Abstract
Acute lymphoblastic leukemia (ALL) has a bimodal age distribution with a peak occurring during early childhood and a second peak after age 45. Although all patients are treated with similar intensive chemotherapy regimens, good outcomes have occurred more frequently in children than adults. Most children with ALL have been able to achieve a complete remission (CR) with an induction rate of about 98% and a 5-year estimated event-free survival rate (EFS) rate of about 80%. Unfortunately, the results for adults are less encouraging. Current adult treatment regimens result in CR rates approaching 80%, with EFS at 5 years of only 30% to 40%. Regardless of age, patients with relapsed or refractory ALL have extremely poor outcomes, because CR rates are low and seldom durable. Clearly, new agents are required to improve the outcome of patients with relapsed or refractory ALL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
